Ole Jannik Bjerrum

Ole Jannik Bjerrum

Professor emeritus

  • Translational Pharmacology

    Jagtvej 160, 2100 København Ø

    Phone: +45 35 33 63 20

  1. Published

    A Paradigm Shift Towards Patient Involvement in Medicines Development and Regulatory Science: Workshop Proceedings and Commentary

    Borup, G., Bach, K. F., Schmiegelow, M., Wallach-Kildemoes, Helle, Bjerrum, Ole Jannik & Westergaard, N., May 2016, In : Therapeutic Innovation & Regulatory Science. 50, 3, p. 304-311 8 p.

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Published

    A novel inhibitor of advanced glycation end- product formation inhibits mesenteric vascular hypertrophy in experimental diabetes

    Bjerrum, Ole Jannik, 1999, In : Diabetologica. 42, p. 472-479 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    A simple method for the preparation and purification of C1 complement cleaved beta 2-microglobulin from human serum.

    Nissen, M. H., Johansen, B. & Bjerrum, Ole Jannik, 1997, In : Journal of Immunological Methods. 205, 1, p. 29-33 4 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Alleviation of nociception in rats by treatment with ceftriaxone, a ß-lactam that promote the expression of the excitatory amino acid transporter 2

    Bjerrum, Ole Jannik, Abrahamsen, B. & Honoré, P. G. H., Nov 2011.

    Research output: Contribution to conferencePosterCommunication

  5. Published

    An analysis of the fixed-dose combinations authorized by the European Union, 2009-14: A Focus on benefit-risk and clinial development condition

    Sawicki-Wrzask, D., Thomsen, M. & Bjerrum, Ole Jannik, 2015, In : Therapeutic Innovation & Regulatory Science. 49, 4, p. 553-559 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA's and FDA's Views on Initial Dual-Therapy

    Bjerrum, Ole Jannik, Eichendorff, S. & Alkis, N. B., Mar 2020, In : Therapeutic Innovation & Regulatory Science. 54, 2, p. 297-302 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Beta-lactam antibiotic as dose dependent analgesic treatment of neuropathic pain

    Bjerrum, Ole Jannik, Abrahamsen, B. & Honoré, P. G. H., 2011.

    Research output: Contribution to conferencePosterResearchpeer-review

  8. Published

    Bivirkningsmonitorering af lægemidler: en ny udfordring af apoteksfarmaceuter

    Christensen, S. T. & Bjerrum, Ole Jannik, 2009, In : Lægemiddelforskning. p. 49-51

    Research output: Contribution to journalJournal articleCommunication

  9. Published

    Blå medicin mod smerter

    Boulakou, A., Bjerrum, Ole Jannik & Honoré, P. G. H., 2012, In : Lægemiddelforskning. 2012, p. 18-19 2 p.

    Research output: Contribution to journalJournal articleCommunication

  10. Published

    Body of evidence and approaches applied in the clinical development programme of fixed-dose combinations in the European Union from 2010 to 2016

    Nøhr-Nielsen, A., De Bruin, Marie Louise (Marieke), Thomsen, M., Pipper, C. B., Lange, Theis, Bjerrum, Ole Jannik & Lund, Trine Meldgaard, 2019, In : British Journal of Clinical Pharmacology. 85, 8, p. 1829-1840 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 4 5 6 7 8 9 Next

ID: 1302721